attexis® – the first permanently listed digital health application for adults with ADHD

As Europe’s market leader in ADHD⁽¹⁾, MEDICE now offers a flexible therapy for those affected, thereby further expanding its broad range of treatment options for this indication. Since 6 August 2025, all statutory health insurers and many private insurers have covered the cost of attexis®.

DiGA attexis® delivers sustainable benefits

attexis® provides patients aged 18 and over with an individualised, digital therapy for everyday support – focusing on effective daily structuring, symptom management and strengthening self-management in accordance with the S3 guideline⁽²⁾.

The programme comprises six interactive conversations in the form of digital therapeutic dialogues. Users start by answering an initial question, on the basis of which they are given tailored content adapted to their individual needs and challenges. As the dialogues progress, content can be further personalised by selecting suitable answers. Weekly reflections and progress overviews make developmental steps visible and boost motivation.

With planning tools, checklists and routines, attexis® supports daily structure and the transfer of therapeutic content into everyday life. Practical materials such as exercises and audio files facilitate integration and promote lasting change.

“We also want to offer adults an additional, targeted digital therapy – especially in view of the often months-long waiting times for a therapy place. With this solution, we are supplementing treatment options and expanding the possibilities for continuous and multimodal therapy,” says Dr Katja Pütter-Ammer, Managing Partner of MEDICE.

attexis® – a digital companion for everyday life with adult ADHD

Based on effective psychological and psychotherapeutic treatment methods, attexis® is aimed at adults with ADHD, with or without medication. The programme offers continuous therapeutic support both within and outside psychiatric consultations: patients can use attexis® even before starting pharmacological and/or psychotherapeutic treatment, bridging waiting times and receiving acute support. At the same time, attexis® enables supportive treatment between therapy sessions as well as aftercare.

For doctors, this creates an additional, evidence-based, multimodal treatment option that makes healthcare more efficient and resource-friendly.

Evidence-based efficacy

The efficacy of attexis® was demonstrated in a randomised controlled trial: use of attexis® in addition to “treatment as usual” (TAU) led to a significant reduction in core ADHD symptoms, with a large effect size compared with TAU alone⁽³⁾.

Secondary endpoints – “social and occupational functioning”, “health-related quality of life”, “depressive symptoms” and “self-esteem” – also improved significantly compared with TAU.

As a pioneer in digital health solutions, MEDICE – The Health Family – continues to build on its successes: only recently, the company received approval for hiToco®, the first DiGA for parents of children with ADHD. With attexis®, MEDICE is now expanding its offering for the treatment of adult ADHD patients – a success based, among other things, on many years of expertise and considerable competence in pharmacological ADHD therapy.

attexis® was developed by GAIA under the leadership of Dr Gitta Jacob. The study was conducted together with PD Dr Eva Fassbinder (Centre for Integrative Psychiatry Kiel), Dipl.-Psych. Roberto D’Amelio (Saarland University Hospital and Medical Faculty of Saarland University, Department of Internal Medicine IV) and Prof. Dr Petra Retz-Junginger (Saarland University Hospital and Medical Faculty of Saarland University, Forensic Psychology and Psychiatry). GAIA is a world-leading developer of digital therapies based on established psychological and psychotherapeutic methods and current scientific standards.

“ADHD is often associated with considerable everyday strain and reduced quality of life. For these people, the permanent approval of attexis® marks a milestone in their care. For the first time, patients and their healthcare providers have permanent access to a digital therapy with proven symptom reduction and comprehensive benefits for care,” says Dr Mario Weiss, CEO of GAIA.

(1) IQVIA Midas, Sales in standard units, Q1/2025

(2) ATTEXIS https://de.attexis.com (Last access 08/01/2025)

(3) ATTEXIS https://de.attexis.com (Last access 08/08/2025)

For the sake of readability, the simultaneous use of the masculine, feminine and diverse forms (m/f/d) is omitted. All personal designations apply equally to all genders.